The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction

被引：32

作者：

Brownell, Nicholas K. ^{[1
]}

Ziaeian, Boback ^{[1
]}

Fonarow, Gregg C. ^{[1
,2
,3
]}

机构：

[1] Univ Calif Angeles UCLA, Div Cardiol, Los Angeles, CA USA

[2] Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA

[3] Ronald Reagan UCLA Med Ctr, 757 Westwood Plaza, Los Angeles, CA 90095 USA

来源：

CARDIAC FAILURE REVIEW | 2021年 / 7卷

关键词：

Heart failure; guideline-directed medical therapy; comprehensive disease-modifying medical therapy; rates of use; cost benefits; early treatment initiation; RANDOMIZED INTERVENTION TRIAL; ALL-CAUSE READMISSION; COST-EFFECTIVENESS; OPTIMAL IMPLEMENTATION; HOSPITALIZED-PATIENTS; BETA-BLOCKERS; CARVEDILOL; MORTALITY; SACUBITRIL/VALSARTAN; GUIDELINES;

D O I：

10.15420/cfr.2021.18

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There are gaps in the use of therapies that save lives and improve quality of life for patients with heart failure with reduced ejection fraction, both in the US and abroad. The evidence is clear that initiation and titration of guideline-directed medical therapy (GDMT) and comprehensive disease-modifying medical therapy (CDMMT) to maximally tolerated doses improves patient-focused outcomes, yet observational data suggest this does not happen. The purpose of this review is to describe the gap in the use of optimal treatment worldwide and discuss the benefits of newer heart failure therapies including angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors. It will also cover the efficacy and safety of such treatments and provide potential pathways for the initiation and rapid titration of GDMT/CDMMT.

引用

页数：8

共 79 条

[1] An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction The EPIC-HF Trial [J].

Allen, Larry A. ;

Venechuk, Grace ;

McIlvennan, Colleen K. ;

Page, Robert L., II ;

Knoepke, Christopher E. ;

Helmkamp, Laura J. ;

Khazanie, Prateeti ;

Peterson, Pamela N. ;

Pierce, Kenneth ;

Harger, Geoffrey ;

Thompson, Jocelyn S. ;

Dow, Tristan J. ;

Richards, Lance ;

Huang, Janice ;

Strader, James R. ;

Trinkley, Katy E. ;

Kao, David P. ;

Magid, David J. ;

Buttrick, Peter M. ;

Matlock, Daniel D. .

CIRCULATION, 2021, 143 (05) :427-437

[2]

American Medical Association, 2017, Prior authorization and utilization management reform principles

[3] ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines [J].

Anderson, Jeffrey L. ;

Heidenreich, Paul A. ;

Barnett, Paul G. ;

Creager, Mark A. ;

Fonarow, Gregg C. ;

Gibbons, Raymond J. ;

Halperin, Jonathan L. ;

Hlatky, Mark A. ;

Jacobs, Alice K. ;

Mark, Daniel B. ;

Masoudi, Frederick A. ;

Peterson, Eric D. ;

Shaw, Leslee J. .

CIRCULATION, 2014, 129 (22) :2329-+

[4] Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction [J].

Balakumaran, Kathir ;

Patil, Aadhar ;

Marsh, Shannon ;

Ingrassia, Joseph ;

Kuo, Chia-Ling ;

Jacoby, Daniel Louis ;

Arora, Sabeena ;

Soucier, Richard .

IJC HEART & VASCULATURE, 2019, 22 :1-5

[5] Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure [J].

Banka, Gaurav ;

Heidenreich, Paul A. ;

Fonarow, Gregg C. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (13) :1440-1446

[6] Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [J].

Bassi, Nikhil S. ;

Ziaeian, Boback ;

Yancy, Clyde W. ;

Fonarow, Gregg C. .

JAMA CARDIOLOGY, 2020, 5 (08) :948-951

[7]

Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746]

[8] Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction [J].

Berg, David D. ;

Jhund, Pardeep S. ;

Docherty, Kieran F. ;

Murphy, Sabina A. ;

Verma, Subodh ;

Inzucchi, Silvio E. ;

Kober, Lars ;

Kosiborod, Mikhail N. ;

Langkilde, Anna Maria ;

Martinez, Felipe A. ;

Bengtsson, Olof ;

Ponikowski, Piotr ;

Sjostrand, Mikaela ;

Solomon, Scott D. ;

McMurray, John J. V. ;

Sabatine, Marc S. .

JAMA CARDIOLOGY, 2021, 6 (05) :499-507

[9] Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization [J].

Bhagat, Aditi A. ;

Greene, Stephen J. ;

Vaduganathan, Muthiah ;

Fonarow, Gregg C. ;

Butler, Javed .

JACC-HEART FAILURE, 2019, 7 (01) :1-12

[10] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Steg, P. Gabriel ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Voors, Adriaan A. ;

Metra, Marco ;

Lund, Lars H. ;

Komajda, Michel ;

Testani, Jeffrey M. ;

Wilcox, Christopher S. ;

Ponikowski, Piotr ;

Lopes, Renato D. ;

Verma, Subodh ;

Lapuerta, Pablo ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :117-128

← 1 2 3 4 5 6 7 8 →